Inflammatory Bowel Disease

LAS VEGAS — Inflammatory bowel disease clinical trials underrepresent racial and ethnic minority groups, according to a presentation at the ACG Annual Scientific Meeting.

LAS VEGAS — In this video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discussed a study assessing the investigational live microbiota-based biotherapeutic, RBX2660 for the treatment of Clostridioides difficile, at the ACG Annual Scientific Meeting.

LAS VEGAS – In this video exclusive, Miguel Regueiro, MD, discussed a study assessing the risk of severe disease in postoperative patients with Crohn’s disease with isolated anastomotic disease.

In a video exclusive, Remo Panaccione, MD, University of Calgary, discusses his research showing Skyrizi bested placebo in inducing clinical remission in patients with Crohn’s disease.

Compared with standard of care, group cognitive behavioral therapy decreased psychological distress and improved overall health among patients with inflammatory bowel disease, according to findings presented at UEG Week Virtual.

Abivax announced updates on ABX464 for the management of moderate to severe ulcerative colitis.

Patients with ulcerative colitis following a novel diet achieved higher clinical remission and mucosal healing compared with patients who received a single donor fecal transplantation, with or without diet, according to a study.

Zeposia compared with placebo was more effective as an induction and maintenance therapy in patients with moderately to severely active ulcerative colitis, according to a study published in The New England Journal of Medicine.

Alcohol consumption increased the risk for microscopic colitis, according to a study published in Inflammatory Bowel Disease.

Healio Gastroenterology presents the following account of our latest inflammatory bowel disease coverage.